Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.

Thumbnail
View/Open
Date
2016-06
ICR Author
Author
Spain, L
Larkin, J
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/574
DOI
Collections
Subject
Humans
Melanoma
Antibodies, Monoclonal
Treatment Outcome
Immunotherapy
Survival Analysis
Clinical Trials as Topic
CTLA-4 Antigen
Antibodies, Monoclonal, Humanized
Programmed Cell Death 1 Receptor
Drug-Related Side Effects and Adverse Reactions
Ipilimumab
B7-H1 Antigen
Nivolumab
Research team
Melanoma and Kidney Cancer
Language
eng
License start date
2016-06
Citation
Immunotherapy, 2016, 8 (6), pp. 677 - 679